98 related articles for article (PubMed ID: 23288634)
1. Update on clinical trials: genetic targets in breast cancer.
Lim B; Cream LV; Harvey HA
Adv Exp Med Biol; 2013; 779():35-54. PubMed ID: 23288634
[TBL] [Abstract][Full Text] [Related]
2. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
3. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches.
Mullan PB; Millikan RC
Cell Mol Life Sci; 2007 Dec; 64(24):3219-32. PubMed ID: 17957336
[TBL] [Abstract][Full Text] [Related]
6. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
Eroles P; Bosch A; Pérez-Fidalgo JA; Lluch A
Cancer Treat Rev; 2012 Oct; 38(6):698-707. PubMed ID: 22178455
[TBL] [Abstract][Full Text] [Related]
7. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients.
Elesawy BH; Abd El hafez A; Shawky Ael-A; Arafa M
Ann Diagn Pathol; 2014 Feb; 18(1):21-6. PubMed ID: 24321463
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
11. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
12. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
14. Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.
Nienhuis HH; Gaykema SB; Timmer-Bosscha H; Jalving M; Brouwers AH; Lub-de Hooge MN; van der Vegt B; Overmoyer B; de Vries EG; Schröder CP
Pharmacol Ther; 2015 Mar; 147():63-79. PubMed ID: 25444756
[TBL] [Abstract][Full Text] [Related]
15. Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.
Braunstein LZ; Taghian AG
Semin Radiat Oncol; 2016 Jan; 26(1):9-16. PubMed ID: 26617205
[TBL] [Abstract][Full Text] [Related]
16. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
Verma S; Bal A; Joshi K; Arora S; Singh G
APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification of infiltrating breast cancer: toward personalized therapy.
Trop I; LeBlanc SM; David J; Lalonde L; Tran-Thanh D; Labelle M; El Khoury MM
Radiographics; 2014; 34(5):1178-95. PubMed ID: 25208275
[TBL] [Abstract][Full Text] [Related]
20. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.
Colombo M; Corsi F; Foschi D; Mazzantini E; Mazzucchelli S; Morasso C; Occhipinti E; Polito L; Prosperi D; Ronchi S; Verderio P
Pharmacol Res; 2010 Aug; 62(2):150-65. PubMed ID: 20117211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]